141 related articles for article (PubMed ID: 31788048)
1. Impact of antiretroviral drugs on PD-L1 expression and copy number gains with clinical outcomes in HIV-positive and -negative locally advanced cervical cancers.
Loharamtaweethong K; Vinyuvat S; Thammasiri J; Chitpakdee S; Supakatitham C; Puripat N
Oncol Lett; 2019 Dec; 18(6):5747-5758. PubMed ID: 31788048
[TBL] [Abstract][Full Text] [Related]
2. PD-L1 protein expression and copy number gains in HIV-positive locally advanced cervical cancer.
Loharamtaweethong K; Puripat N; Praditphol N; Thammasiri J; Tangitgamol S
Ther Adv Med Oncol; 2020; 12():1758835920963001. PubMed ID: 33149767
[TBL] [Abstract][Full Text] [Related]
3. Prognostic significance of PD-L1 protein expression and copy number gains in locally advanced cervical cancer.
Loharamtaweethong K; Supakatitham C; Vinyuvat S; Puripat N; Tanvanich S; Sitthivilai U
Asian Pac J Allergy Immunol; 2021 Dec; 39(4):309-318. PubMed ID: 31586491
[TBL] [Abstract][Full Text] [Related]
4. Clinical significance of PD-L1 and PD-L2 copy number gains in non-small-cell lung cancer.
Inoue Y; Yoshimura K; Mori K; Kurabe N; Kahyo T; Mori H; Kawase A; Tanahashi M; Ogawa H; Inui N; Funai K; Shinmura K; Niwa H; Suda T; Sugimura H
Oncotarget; 2016 May; 7(22):32113-28. PubMed ID: 27050074
[TBL] [Abstract][Full Text] [Related]
5. Prognostic value of programmed death ligand-1 and programmed death-1 expression in patients with upper tract urothelial carcinoma.
Campedel L; Compérat E; Cancel-Tassin G; Varinot J; Pfister C; Delcourt C; Gobet F; Roumiguié M; Patard PM; Daniel G; Bigot P; Carrouget J; Eymerit C; Larré S; Léon P; Durlach A; Ruffion A; de Mazancourt ES; Decaussin-Petrucci M; Bessède T; Lebacle C; Ferlicot S; Robert G; Vuong NS; Philip M; Crouzet S; Matillon X; Mège-Lechevallier F; Lang H; Mouracade P; Lindner V; Gougis P; Cussenot O; Rouprêt M; Seisen T
BJU Int; 2023 Nov; 132(5):581-590. PubMed ID: 37488983
[TBL] [Abstract][Full Text] [Related]
6. Prognostic Role of Programmed Death Ligand-1 Expression in Breast Cancer: A Systematic Review and Meta-Analysis.
Li X; Li M; Lian Z; Zhu H; Kong L; Wang P; Yu J
Target Oncol; 2016 Dec; 11(6):753-761. PubMed ID: 27422273
[TBL] [Abstract][Full Text] [Related]
7. PD-1 and PD-L1 Expression Predicts Radiosensitivity and Clinical Outcomes in Head and Neck Cancer and is Associated with HPV Infection.
Lyu X; Zhang M; Li G; Jiang Y; Qiao Q
J Cancer; 2019; 10(4):937-948. PubMed ID: 30854100
[No Abstract] [Full Text] [Related]
8. Predictive value of MLH1 and PD-L1 expression for prognosis and response to preoperative chemotherapy in gastric cancer.
Hashimoto T; Kurokawa Y; Takahashi T; Miyazaki Y; Tanaka K; Makino T; Yamasaki M; Nakajima K; Ikeda JI; Mori M; Doki Y
Gastric Cancer; 2019 Jul; 22(4):785-792. PubMed ID: 30617648
[TBL] [Abstract][Full Text] [Related]
9. Prognostic and Clinicopathological Significance of PD-L1 in Patients With Bladder Cancer: A Meta-Analysis.
Zhu L; Sun J; Wang L; Li Z; Wang L; Li Z
Front Pharmacol; 2019; 10():962. PubMed ID: 31616289
[No Abstract] [Full Text] [Related]
10. Programmed death ligand 1 expression in esophageal cancer following definitive chemoradiotherapy: Prognostic significance and association with inflammatory biomarkers.
Tang Y; Li G; Wu S; Tang L; Zhang N; Liu J; Zhang S; Yao L
Oncol Lett; 2018 Apr; 15(4):4988-4996. PubMed ID: 29552135
[TBL] [Abstract][Full Text] [Related]
11. Prognostic impact of CD8 and programmed death-ligand 1 expression in patients with resectable non-small cell lung cancer.
Kim SH; Go SI; Song DH; Park SW; Kim HR; Jang I; Kim JD; Lee JS; Lee GW
Br J Cancer; 2019 Mar; 120(5):547-554. PubMed ID: 30745585
[TBL] [Abstract][Full Text] [Related]
12. Atezolizumab versus docetaxel in patients with previously treated non-small-cell lung cancer (OAK): a phase 3, open-label, multicentre randomised controlled trial.
Rittmeyer A; Barlesi F; Waterkamp D; Park K; Ciardiello F; von Pawel J; Gadgeel SM; Hida T; Kowalski DM; Dols MC; Cortinovis DL; Leach J; Polikoff J; Barrios C; Kabbinavar F; Frontera OA; De Marinis F; Turna H; Lee JS; Ballinger M; Kowanetz M; He P; Chen DS; Sandler A; Gandara DR;
Lancet; 2017 Jan; 389(10066):255-265. PubMed ID: 27979383
[TBL] [Abstract][Full Text] [Related]
13. Positive PD-L1 expression is predictive for patients with advanced EGFR wild-type non-small cell lung cancer treated with gemcitabine and cisplatin.
Qiu Y; Jiang J; Zhang M; Qin Y
Oncol Lett; 2019 Jul; 18(1):161-168. PubMed ID: 31289485
[TBL] [Abstract][Full Text] [Related]
14. PD-L1 and PD-L2 Genetic Alterations Define Classical Hodgkin Lymphoma and Predict Outcome.
Roemer MG; Advani RH; Ligon AH; Natkunam Y; Redd RA; Homer H; Connelly CF; Sun HH; Daadi SE; Freeman GJ; Armand P; Chapuy B; de Jong D; Hoppe RT; Neuberg DS; Rodig SJ; Shipp MA
J Clin Oncol; 2016 Aug; 34(23):2690-7. PubMed ID: 27069084
[TBL] [Abstract][Full Text] [Related]
15. The prognostic role of PD-L1 expression for survival in head and neck squamous cell carcinoma: A systematic review and meta-analysis.
Yang WF; Wong MCM; Thomson PJ; Li KY; Su YX
Oral Oncol; 2018 Nov; 86():81-90. PubMed ID: 30409325
[TBL] [Abstract][Full Text] [Related]
16. Prognostic impacts of the combined positive score and the tumor proportion score for programmed death ligand-1 expression by double immunohistochemical staining in patients with advanced gastric cancer.
Yamashita K; Iwatsuki M; Harada K; Eto K; Hiyoshi Y; Ishimoto T; Nagai Y; Iwagami S; Miyamoto Y; Yoshida N; Komohara Y; Ajani JA; Baba H
Gastric Cancer; 2020 Jan; 23(1):95-104. PubMed ID: 31451991
[TBL] [Abstract][Full Text] [Related]
17. Programmed death-ligand 1 expression in the tumour stroma of colorectal liver oligometastases and its association with prognosis after liver resection.
Peng JH; Tai Y; Zhao YX; Luo BJ; Ou QJ; Pan ZZ; Zhang L; Lu ZH
Gastroenterol Rep (Oxf); 2021 Oct; 9(5):443-450. PubMed ID: 34733530
[TBL] [Abstract][Full Text] [Related]
18. Atezolizumab versus docetaxel for patients with previously treated non-small-cell lung cancer (POPLAR): a multicentre, open-label, phase 2 randomised controlled trial.
Fehrenbacher L; Spira A; Ballinger M; Kowanetz M; Vansteenkiste J; Mazieres J; Park K; Smith D; Artal-Cortes A; Lewanski C; Braiteh F; Waterkamp D; He P; Zou W; Chen DS; Yi J; Sandler A; Rittmeyer A;
Lancet; 2016 Apr; 387(10030):1837-46. PubMed ID: 26970723
[TBL] [Abstract][Full Text] [Related]
19. The Association Between PD-L1 Expression and the Clinical Outcomes to Vascular Endothelial Growth Factor-Targeted Therapy in Patients With Metastatic Clear Cell Renal Cell Carcinoma.
Shin SJ; Jeon YK; Cho YM; Lee JL; Chung DH; Park JY; Go H
Oncologist; 2015 Nov; 20(11):1253-60. PubMed ID: 26424759
[TBL] [Abstract][Full Text] [Related]
20. Genetic Basis for PD-L1 Expression in Squamous Cell Carcinomas of the Cervix and Vulva.
Howitt BE; Sun HH; Roemer MG; Kelley A; Chapuy B; Aviki E; Pak C; Connelly C; Gjini E; Shi Y; Lee L; Viswanathan A; Horowitz N; Neuberg D; Crum CP; Lindeman NL; Kuo F; Ligon AH; Freeman GJ; Hodi FS; Shipp MA; Rodig SJ
JAMA Oncol; 2016 Apr; 2(4):518-22. PubMed ID: 26913631
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
